Viridian Therapeutics, Inc. $VRDN Shares Acquired by J. Safra Sarasin Holding AG

Key Points

• J. Safra Sarasin Holding AG increased its stake in Viridian Therapeutics by 135.5%, now owning 171,119 shares valued at approximately $2.39 million.
• Analysts have mixed ratings for VRDN shares, with price target revisions including a decrease by Royal Bank of Canada from $45.00 to $41.00 and an increase by Goldman Sachs from $27.00 to $30.00.
• Viridian Therapeutics reported a quarterly EPS of ($1.00) and revenue of $0.08 million, aligning with analyst estimates and showing a 4.2% year-over-year revenue increase.

J. Safra Sarasin Holding AG grew its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 135.5% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 171,119 shares of the company's stock after buying an additional 98,447 shares during the period. J. Safra Sarasin Holding AG owned 0.21% of Viridian Therapeutics worth $2,392,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the business. Rhumbline Advisers boosted its stake in Viridian Therapeutics by 4.6% during the 1st quarter. Rhumbline Advisers now owns 104,559 shares of the company's stock worth $1,409,000 after purchasing an additional 4,621 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Viridian Therapeutics by 12.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 130,570 shares of the company's stock worth $1,760,000 after purchasing an additional 14,788 shares during the period. Exome Asset Management LLC acquired a new stake in Viridian Therapeutics during the 1st quarter worth $2,929,000. Goldman Sachs Group Inc. boosted its stake in Viridian Therapeutics by 33.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,231,092 shares of the company's stock worth $16,595,000 after purchasing an additional 310,998 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Viridian Therapeutics by 1.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,276 shares of the company's stock worth $669,000 after purchasing an additional 876 shares during the period.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on VRDN shares. Royal Bank Of Canada decreased their price target on shares of Viridian Therapeutics from $45.00 to $41.00 and set an "outperform" rating for the company in a research note on Thursday, August 7th. Needham & Company LLC decreased their price target on shares of Viridian Therapeutics from $36.00 to $34.00 and set a "buy" rating for the company in a research note on Wednesday, August 6th. Wells Fargo & Company reduced their target price on shares of Viridian Therapeutics from $27.00 to $26.00 and set an "equal weight" rating for the company in a research note on Thursday, August 7th. The Goldman Sachs Group raised their target price on shares of Viridian Therapeutics from $27.00 to $30.00 and gave the stock a "buy" rating in a research note on Thursday, August 7th. Finally, Oppenheimer raised their target price on shares of Viridian Therapeutics from $28.00 to $32.00 and gave the stock an "outperform" rating in a research note on Thursday, August 7th. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $34.88.

Viridian Therapeutics Stock Performance

Shares of VRDN opened at $21.65 on Friday. The company has a market capitalization of $1.77 billion, a PE ratio of -5.65 and a beta of 0.49. Viridian Therapeutics, Inc. has a 52-week low of $9.90 and a 52-week high of $27.20. The company has a quick ratio of 11.01, a current ratio of 11.01 and a debt-to-equity ratio of 0.04. The company has a 50-day simple moving average of $18.76 and a 200-day simple moving average of $15.80.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($1.00) EPS for the quarter, hitting analysts' consensus estimates of ($1.00). The business had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.05 million. Viridian Therapeutics had a negative net margin of 112,806.88% and a negative return on equity of 78.95%. The company's quarterly revenue was up 4.2% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.81) earnings per share. Equities research analysts predict that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.